Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Analysis of plasma surfactant protein D levels in lung transplant recipients.

Bejvl I, Weseslindtner L, Strassl R, Jaksch P, Kundi M, Klepetko W, Puchhammer-Stöckl E.

Transpl Infect Dis. 2013 Dec;15(6):645-51. doi: 10.1111/tid.12132. Epub 2013 Sep 13.

PMID:
24028302
2.

Prognostic value of serum surfactant protein D level prior to transplant for the development of bronchiolitis obliterans syndrome and idiopathic pneumonia syndrome following allogeneic hematopoietic stem cell transplantation.

Nakane T, Nakamae H, Kamoi H, Koh H, Takeoka Y, Sakamoto E, Kanashima H, Nakamae M, Ohta K, Terada Y, Koh KR, Yamane T, Hino M.

Bone Marrow Transplant. 2008 Jul;42(1):43-9. doi: 10.1038/bmt.2008.73. Epub 2008 Mar 17.

PMID:
18347569
3.

Bronchoalveolar lavage fluid proteome in bronchiolitis obliterans syndrome: possible role for surfactant protein A in disease onset.

Meloni F, Salvini R, Bardoni AM, Passadore I, Solari N, Vitulo P, Oggionni T, Viganò M, Pozzi E, Fietta AM.

J Heart Lung Transplant. 2007 Nov;26(11):1135-43.

PMID:
18022079
4.

Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis.

Sims MW, Beers MF, Ahya VN, Kawut SM, Sims KD, Lederer DJ, Palmer SM, Wille K, Lama VN, Shah PD, Orens JB, Bhorade S, Crespo M, Weinacker A, Demissie E, Bellamy S, Christie JD, Ware LB; Lung Transplant Outcomes Group.

Chest. 2011 Aug;140(2):489-96. doi: 10.1378/chest.10-2065. Epub 2011 Feb 24.

5.

Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome.

Valentine VG, Gupta MR, Walker JE Jr, Seoane L, Bonvillain RW, Lombard GA, Weill D, Dhillon GS.

J Heart Lung Transplant. 2009 Feb;28(2):163-9. doi: 10.1016/j.healun.2008.11.907.

PMID:
19201342
6.

Risk factors for the development of obliterative bronchiolitis after lung transplantation.

Girgis RE, Tu I, Berry GJ, Reichenspurner H, Valentine VG, Conte JV, Ting A, Johnstone I, Miller J, Robbins RC, Reitz BA, Theodore J.

J Heart Lung Transplant. 1996 Dec;15(12):1200-8.

PMID:
8981205
7.

Clinical and immunological evaluation of 12-month azithromycin therapy in chronic lung allograft rejection.

Federica M, Nadia S, Monica M, Alessandro C, Tiberio O, Francesco B, Mario V, Maria FA.

Clin Transplant. 2011 Jul-Aug;25(4):E381-9. doi: 10.1111/j.1399-0012.2011.01435.x. Epub 2011 Mar 21.

PMID:
21418327
8.

Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation.

Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC.

Transplantation. 2003 Jun 27;75(12):2064-8.

PMID:
12829913
9.

Increased plasma mannose binding lectin levels are associated with bronchiolitis obliterans after lung transplantation.

Budd SJ, Aris RM, Medaiyese AA, Tilley SL, Neuringer IP.

Respir Res. 2012 Jul 4;13:56. doi: 10.1186/1465-9921-13-56.

10.

Immediate postoperative inflammatory response predicts long-term outcome in lung-transplant recipients.

Hall DJ, Baz M, Daniels MJ, Staples ED, Klodell CT, Moldawer LL, Beaver TM.

Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):603-7. Epub 2012 Jul 19.

11.

Plasma surfactant protein levels and clinical outcomes in patients with acute lung injury.

Eisner MD, Parsons P, Matthay MA, Ware L, Greene K; Acute Respiratory Distress Syndrome Network.

Thorax. 2003 Nov;58(11):983-8.

12.

Clara cell secretory protein and surfactant protein-D do not predict bronchiolitis obliterans syndrome after lung transplantation.

Paantjens AW, Otten HG, van Ginkel WG, van Kessel DA, van den Bosch JM, Kwakkel-van Erp JM, van de Graaf EA.

Transplantation. 2010 Aug 15;90(3):340-2. doi: 10.1097/TP.0b013e3181e1b9f8. No abstract available.

PMID:
20683434
13.

Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation.

Bando K, Paradis IL, Komatsu K, Konishi H, Matsushima M, Keena RJ, Hardesty RL, Armitage JM, Griffith BP.

J Thorac Cardiovasc Surg. 1995 Jan;109(1):49-57; discussion 57-9.

14.

Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients.

Chaparro C, Chamberlain D, Maurer J, Winton T, Dehoyos A, Kesten S.

Chest. 1996 Nov;110(5):1150-4.

PMID:
8915212
15.

Lung transplantation for cystic fibrosis: 6-year follow-up.

Quattrucci S, Rolla M, Cimino G, Bertasi S, Cingolani S, Scalercio F, Venuta F, Midulla F.

J Cyst Fibros. 2005 May;4(2):107-14.

16.

Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant.

Charlson ES, Diamond JM, Bittinger K, Fitzgerald AS, Yadav A, Haas AR, Bushman FD, Collman RG.

Am J Respir Crit Care Med. 2012 Sep 15;186(6):536-45. doi: 10.1164/rccm.201204-0693OC. Epub 2012 Jul 12.

18.

Are heart-lung transplant recipients protected from developing bronchiolitis obliterans syndrome?

Moffatt-Bruce SD, Karamichalis J, Robbins RC, Whyte RI, Theodore J, Reitz BA.

Ann Thorac Surg. 2006 Jan;81(1):286-91; discussion 291.

PMID:
16368382
19.

Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis.

Manuel O, Kumar D, Moussa G, Chen MH, Pilewski J, McCurry KR, Studer SM, Crespo M, Husain S, Humar A.

Transplantation. 2009 Mar 15;87(5):719-25. doi: 10.1097/TP.0b013e3181963262.

PMID:
19295317
20.

Donor surfactant protein D (SP-D) polymorphisms are associated with lung transplant outcome.

Aramini B, Kim C, Diangelo S, Petersen E, Lederer DJ, Shah L, Robbins H, Floros J, Arcasoy SM, Sonett JR, D'Ovidio F.

Am J Transplant. 2013 Aug;13(8):2130-6. doi: 10.1111/ajt.12326. Epub 2013 Jul 10.

Items per page

Supplemental Content

Write to the Help Desk